SoniVie, an Italy and Israel-run med tech seeking to treat hypertension through the use of ultrasound, has closed a $60 million series C round to make headway toward its clinical and regulatory pipeline.
Hypertension refers to high blood pressure, abnormally constricted nerves and obstructions in blood flow to vital organs. Often termed a silent killer because it presents no prior symptoms, left unmanaged it can cause stroke, kidney failure and heart attacks.
Clinicians traditionally used ultrasound for non-invasive imaging scans of the body, but high precision formats hold promise in addressing intractable diagnoses.
SoniVie's proposed ultrasound device, TIVUS, targets the patient's renal artery, deploying ultrasound to ablate nerves in that area.
It says this should result in reduced blood pressure and also is adaptable; future iterations could tackle denervation in the lung arteries, also treating chronic obstructive pulmonary disease exhibited in co-morbidity with chronic bronchitis.
Speaking on behalf of Andera Partners, Raphaël Wisniewski commented: "SoniVie TIVUS™ has the potential to provide patients and physicians with a safe, efficient and easy to use device.
"We are thrilled to support this talented management together with our syndicate partners and our new board members".
The board is gaining two independent members post-series C fundraise: Raymond Cohen, a consultant from London law firm Linklaters, and Zeev Zehavi, vice president for venture investments at Johnson & Johnson Innovation — JJDC.